Removing Barriers. Expanding Capacity. How Source BioScience Built a Scalable Digital Pathology Network with HALO AP®
Read How Source BioScience Built a Scalable Digital Pathology Network with HALO AP®. Supporting over 90 NHS Trusts.
Clinical
Zero-Click Breast IHC Scoring Is Here: What’s New in HALO Breast IHC AI
In this blog post, we’ll discuss some of the exciting new features and functionalities in the latest release of HALO AP®, the CE-IVDR marked, AI-powered enterprise digital pathology platform from Indica Labs.
Zero-Click Breast IHC Scoring Is Here: What’s New in HALO Breast IHC AI Read More »
HALO AP 2.5: Scaling Digital Pathology with Intelligent Workflow Orchestration
In this blog post, we’ll discuss some of the exciting new features and functionalities in the latest release of HALO AP®, the CE-IVDR marked, AI-powered enterprise digital pathology platform from Indica Labs.
HALO AP 2.5: Scaling Digital Pathology with Intelligent Workflow Orchestration Read More »
HALO AP® 2.5
HALO AP® AI Powered, Pathologist Driven The CE-IVDR marked, AI-powered image management system built to digitize clinical pathology workflows and allow pathologists to work anytime,
Lab Logic Brings Intelligent Case Orchestration to HALO AP® and HALO AP Dx
HALO AP 2.5 introduces Lab Logic. A configuration layer that enables labs to tailor HALO AP® to their preferred workflow, enabling any lab, regardless of case volume, to operate like an automated triage engine, continuously analyzing incoming slides; triggering AI-driven actions; and delivering the right cases to the right experts at the right time.
Lab Logic Brings Intelligent Case Orchestration to HALO AP® and HALO AP Dx Read More »
Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio
Albuquerque, NM, February 10, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the expansion of its macrodissection portfolio with the launch of Breast Macrodissect AI . The suite now includes advanced algorithms for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and breast cancer, with prostate cancer planned for release in early 2026.
Indica Labs Receives FDA Clearance for Enterprise Digital Pathology Platform with Industry Leading DICOM-Compatible Aperio Scanner from Leica Biosystems
ALBUQUERQUE, NM, and VISTA, CA, December 3, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announced today that the Food and Drug Administration (FDA) has issued a 510(k) clearance for the enterprise digital pathology platform HALO AP Dx in conjunction with Leica Biosystems Aperio GT 450 DX Scanner for in-vitro diagnostic use.